In: In vivo CAR-T

Arnovie101

Circunited BioPharma

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Early Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
Reprograms the patient's own immune T cells, inside the body, to hunt one kind of cell, such as cancerous B cells. Standard CAR-T does this in a lab.In vivo CAR-T, mRNA in lipid nanoparticles, target not disclosed
How it’s given
“Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.”In the company’s words, NCT07629596 on ClinicalTrials.gov
Tested for
Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia (AIHA)
Main trialEarly Phase 1
“This is an open lable and single arm study designed to evaluate the safety, PK and PD of Arnovie101 in B cell-mediated Autoimmune Disease”In the company’s words, NCT07629596 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Early Phase 1Recruiting 30 May 2027 Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026

Follow Arnovie101

Following is part of Solo: you see every change to Arnovie101 the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in